<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002999</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000065552</org_study_id>
    <secondary_id>U10CA032102</secondary_id>
    <secondary_id>S9715</secondary_id>
    <nct_id>NCT00002999</nct_id>
  </id_info>
  <brief_title>S9715, Chemotherapy and Radiation Therapy in Treating Patients With Advanced Cancer of the Nasopharynx</brief_title>
  <official_title>S9715, Study of Patients With Advanced Nasopharyngeal Cancers Treated With Chemo-Radiotherapy, Phase II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.&#xD;
      Combining more than one drug and combining chemotherapy with radiation therapy may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in&#xD;
      treating patients with advanced cancer of the nasopharynx.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Gather additional information and experience regarding the preferred treatment&#xD;
      from clinical trial SWOG-8892, chemoradiation for patients with advanced nasopharyngeal&#xD;
      cancers (NPC). II. Evaluate survival and progression-free survival and patterns of tumor&#xD;
      failure in this new group of patients. III. Assess severe or lethal toxicities that may be&#xD;
      encountered after this regimen is employed more widely. IV. Collect NPC tumor specimens for&#xD;
      ongoing and future clinical correlative research.&#xD;
&#xD;
      OUTLINE: Patients receive cisplatin by intravenous infusion on day 1 over a 15-20 minute&#xD;
      period. This is repeated every 21 days for the first three initial treatments. Patients also&#xD;
      receive radiation therapy once daily five times a week during this cycle of treatment.&#xD;
      Approximately three weeks after completion of the above treatment, patients are given&#xD;
      cisplatin by intravenous infusion over 15-20 minutes as above but at a lower dose. On the&#xD;
      same day as cisplatin infusion, patients receive fluorouracil by continuous intravenous&#xD;
      infusion over 24 hours for 4 days in a row. This is repeated every 28 days for a total of 3&#xD;
      treatments. Patients are followed until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: 100 patients will be accrued.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven nasopharyngeal carcinoma (excluding&#xD;
        adenocarcinoma), stage III or IV with no evidence of distant metastatic disease (M0) No&#xD;
        lung, bone, or liver metastases as proven within 42 days of registration by: -CT scan or&#xD;
        nucleotide study of the chest or chest x-ray -liver and bone scan if alkaline phosphatase&#xD;
        is greater than the institutional upper limit of normal (ULN), or if clinically indicated&#xD;
        -liver scan if SGOT is greater than the institutional ULN&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Any age Performance status: SWOG 0-2 Life expectancy: Not&#xD;
        specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count at&#xD;
        least 75,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.6 mg/dL AND/OR&#xD;
        Creatinine clearance at least 50 mL/minute Other: Not pregnant or nursing Women/men of&#xD;
        reproductive potential must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No previous&#xD;
        chemotherapy to the primary site or nodes Endocrine therapy: Not specified Radiotherapy: No&#xD;
        previous radiotherapy (except for nonmelanomatous skin cancer outside of the radiation&#xD;
        therapy treatment volume) Surgery: No previous surgery to the primary site or nodes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhyi Al-Sarraf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Providence Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George L. Adams, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>July 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 5, 2004</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <name_title>Laurence H. Baker, D.O.</name_title>
    <organization>Southwest Oncology Group-Group Chair's Office</organization>
  </responsible_party>
  <keyword>stage III nasopharyngeal cancer</keyword>
  <keyword>stage IV nasopharyngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

